CN-121991862-A - Lactobacillus reuteri FMZ07 and application thereof in antidepressant and intestinal flora improvement

Abstract

The invention discloses lactobacillus reuteri FMZ07 and application thereof in antidepressant and intestinal flora improvement, and belongs to the technical field of biomedicine. The strain is preserved in China general microbiological culture Collection center (CGMCC), the preservation address is CGMCC, the China national academy of sciences of China, first, second, third, and fourth, the Korean area North Star of Beijing, the preservation number is CGMCC No. 37751, the preservation date is 2026, 2, 9 and the taxonomy is named as Lactobacillus reuteri Limosilactobacillus reuteri. The strain provided by the invention can regulate the microorganism-intestine-brain axis through multiple targets, can recover the richness and uniformity of intestinal flora while obviously improving the depression-like behavior of a depression model mouse, and provides a reliable microorganism resource for developing probiotic preparations or medicines for improving depression and assisting in improving the intestinal flora.

Inventors

• ZHOU LI
• LIU ZHONGXUE
• Pang Meiqi
• MA WENJIAN
• SUN HAIFEI
• MENG LINLIN
• SONG YAJIAN
• ZHAO SHANGYU
• LIU JIE

Assignees

• 天津科技大学

Dates

Publication Date

20260508

Application Date

20260408

Claims (6)

1. 1. The Lactobacillus reuteri FMZ07 is characterized in that the strain is preserved in China general microbiological culture Collection center (CGMCC), the preservation address is CGMCC No. North Star, the institute of microorganisms of the third national academy of sciences of West-first-order sciences of the Korean area of Beijing, the preservation number is CGMCC No. 37751, the preservation date is 2026, the 2 nd month 9 days, and the taxonomy is named as Lactobacillus reuteri Limosilactobacillus reuteri.
2. 2. A probiotic preparation comprising lactobacillus reuteri FMZ07 according to claim 1.
3. 3. Use of lactobacillus reuteri FMZ07 as claimed in claim 1 in the manufacture of an antidepressant.
4. 4. Use according to claim 3, wherein the effective dose of lactobacillus reuteri FMZ07 is 1 x 10 9 CFU/kg.
5. 5. Use of lactobacillus reuteri FMZ07 as claimed in claim 1 in the manufacture of a medicament for improving intestinal flora.
6. 6. The use according to claim 5, wherein the effective dose of lactobacillus reuteri FMZ07 is 1 x 10 9 CFU/kg.

Description

Lactobacillus reuteri FMZ07 and application thereof in antidepressant and intestinal flora improvement Technical Field The invention relates to the technical field of biomedicine, in particular to lactobacillus reuteri FMZ07 and application thereof in antidepressant and intestinal flora improvement. Background Depression is one of the most common mental disorders worldwide and is mainly characterized by a marked and persistent depression, and some patients may have self-injury, suicidal behavior, and even psychotic symptoms such as delusions, hallucinations, and the like, which place a heavy burden on individuals, families, and society. The traditional antidepressant has the problems of low effective rate, delayed onset of action, large side effects and the like, and the treatment effect is not ideal. In recent years, with the proposal and development of the theory of microorganism-intestine-brain axis, a brand new view is provided for understanding the pathogenesis of depression and developing novel therapies. The theory states that there is a complex two-way communication network between the gut and brain involving multiple pathways of nerves, endocrine, immune and metabolic. The gut is called the "second brain", and its nervous system possesses more than 1 hundred million neurons and is involved in the synthesis of a variety of neuromodulatory substances. Studies have shown that the intestinal flora is able to influence the metabolism and regulation of gamma-aminobutyric acid (GABA), which is a major inhibitory neurotransmitter in the central nervous system and is crucial for maintaining neuronal excitatory balance and mood stabilization. Current studies indicate that there is a significant difference in gut flora composition from healthy individuals in depressed patients, often manifested by reduced flora diversity, reduced beneficial bacteria, and concomitant impairment of gut barrier function, elevated systemic inflammatory levels, and disturbed neurotransmitter metabolism. Such disorders may affect the function of the gabaergic system and thus be involved in the occurrence of depressive symptoms. Based on this, modulation of intestinal flora by probiotics has become a potentially effective strategy for improving symptoms of depression. In particular, the ingestion of probiotics not only helps to maintain intestinal flora balance, reduce the growth of harmful bacteria, but also produces metabolites beneficial to the brain, such as short chain fatty acids (e.g. acetic acid, propionic acid, butyric acid, etc.) and neuroactive substances (e.g. gamma-aminobutyric acid). These substances affect the emotional and psychological states through the intestinal brain axis. In addition, the positive effects of probiotics on mental health have also been linked to their ability to regulate brain-derived neurotrophic factor (BDNF) levels, which are critical for neuronal survival, growth and differentiation, with changes in levels being closely related to the amelioration of symptoms of depression. Meanwhile, probiotics help to reduce the neuroinflammation level associated with psychological stress by reducing the production of pro-inflammatory factors (such as TNF- α, IL-6), further promoting psychological health. Therefore, how to develop a novel strain with antidepressant effect is a problem to be solved by the person skilled in the art. Disclosure of Invention Accordingly, the present invention aims to provide lactobacillus reuteri FMZ07 and its application in antidepressant and intestinal flora improvement, so as to solve the defects in the prior art. In order to achieve the above purpose, the present invention adopts the following technical scheme: The strain of lactobacillus reuteri FMZ07 is preserved in China general microbiological culture Collection center (CHINA GENERAL Microbiological Culture Collection Center), which is called CGMCC for short, and has a preservation address of CGMCC No. 37751, a preservation date of 2026, 2 months and 9 days, and a taxonomy of lactobacillus reuteri Limosilactobacillus reuteri. The lactobacillus reuteri FMZ07 of the present invention is capable of surviving in simulated gastric acid conditions at a pH of 2.0-3.0 and is tolerant to bile salt environments of 0.1% -0.5%. The lactobacillus reuteri FMZ07 can play the roles of anti-depression and intestinal flora improvement by improving depression-like behaviors, reducing the level of intestinal inflammatory factors, regulating intestinal brain axis related metabolites, maintaining the integrity of intestinal barriers and regulating neurotransmitter related indexes. A probiotic preparation contains the above Lactobacillus reuteri FMZ07. The invention also claims the application of the lactobacillus reuteri FMZ07 in preparing antidepressant drugs. Further, the effective dose of the Lactobacillus reuteri FMZ07 is 1X 10 9 CFU/kg. The invention also claims the application of the lactobacillus reuteri FMZ07 in preparing the intesti